Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer’s disease, failed to meet its primary endpoints. The Swiss pharma company ROG, -3.72% Read more
Tag: Roche
Roche backs 2022 outlook as profit climbs, boosted by diagnostics sales
Roche Holding AG said Thursday that profit for the first half of the year increased as sales grew, mainly driven by the diagnostics division. The Swiss pharmaceutical company ROG, -0.64% Read more